Mitsubishi UFJ Trust & Banking Corp Sells 75,653 Shares of Zoetis Inc. (NYSE:ZTS)

Mitsubishi UFJ Trust & Banking Corp lowered its position in Zoetis Inc. (NYSE:ZTS) by 18.5% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 333,874 shares of the company’s stock after selling 75,653 shares during the period. Mitsubishi UFJ Trust & Banking Corp owned 0.07% of Zoetis worth $52,712,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Oakworth Capital Inc. raised its stake in shares of Zoetis by 128.6% in the first quarter. Oakworth Capital Inc. now owns 160 shares of the company’s stock valued at $25,000 after acquiring an additional 90 shares during the last quarter. Graves Light Private Wealth Management Inc. bought a new position in shares of Zoetis in the fourth quarter valued at approximately $31,000. TRU Independence Asset Management 2 LLC bought a new position in shares of Zoetis in the fourth quarter valued at approximately $31,000. Encompass Wealth Advisors LLC acquired a new stake in shares of Zoetis in the fourth quarter valued at approximately $31,000. Finally, Accel Wealth Management increased its holdings in shares of Zoetis by 97.0% in the first quarter. Accel Wealth Management now owns 197 shares of the company’s stock valued at $31,000 after purchasing an additional 97 shares in the last quarter. Institutional investors own 90.21% of the company’s stock.

Shares of NYSE ZTS opened at $182.10 on Friday. The stock’s fifty day moving average price is $170.37. The company has a market capitalization of $86.46 billion, a PE ratio of 49.08, a price-to-earnings-growth ratio of 3.05 and a beta of 0.64. Zoetis Inc. has a twelve month low of $130.40 and a twelve month high of $182.85. The company has a current ratio of 3.29, a quick ratio of 2.47 and a debt-to-equity ratio of 1.61.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, May 6th. The company reported $1.26 earnings per share for the quarter, topping analysts’ consensus estimates of $1.04 by $0.22. The company had revenue of $1.87 billion for the quarter, compared to analysts’ expectations of $1.73 billion. Zoetis had a net margin of 25.30% and a return on equity of 55.11%. The business’s quarterly revenue was up 22.0% compared to the same quarter last year. During the same period last year, the firm posted $0.95 earnings per share. As a group, analysts forecast that Zoetis Inc. will post 4.5 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 1st. Investors of record on Wednesday, July 21st will be given a $0.25 dividend. The ex-dividend date of this dividend is Tuesday, July 20th. This represents a $1.00 annualized dividend and a yield of 0.55%. Zoetis’s dividend payout ratio is currently 25.97%.

In other Zoetis news, EVP Robert Edward Kelly sold 2,055 shares of the business’s stock in a transaction dated Thursday, April 1st. The shares were sold at an average price of $158.05, for a total transaction of $324,792.75. Also, EVP Heidi C. Chen sold 11,637 shares of the business’s stock in a transaction dated Wednesday, April 21st. The stock was sold at an average price of $170.14, for a total transaction of $1,979,919.18. Following the sale, the executive vice president now directly owns 36,282 shares in the company, valued at $6,173,019.48. The disclosure for this sale can be found here. Insiders sold a total of 19,692 shares of company stock worth $3,319,012 over the last ninety days. 0.21% of the stock is currently owned by insiders.

ZTS has been the subject of a number of research reports. Raymond James raised their price target on shares of Zoetis from $166.00 to $192.00 and gave the company an “outperform” rating in a report on Friday, May 7th. Zacks Investment Research raised shares of Zoetis from a “hold” rating to a “buy” rating and set a $186.00 price target for the company in a report on Tuesday, June 1st. Citigroup lifted their target price on shares of Zoetis from $175.00 to $184.00 in a report on Wednesday, May 12th. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell lifted their target price on shares of Zoetis from $175.00 to $184.00 and gave the stock a “neutral” rating in a report on Wednesday, May 12th. Finally, Bank of America raised shares of Zoetis from a “neutral” rating to a “buy” rating and set a $180.00 target price for the company in a report on Monday, March 8th. Six equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $184.38.

Zoetis Company Profile

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

See Also: Investing in Growth Stocks

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.